Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Taxotere cases. Here at Leading Justice, we can customize your firm’s Taxotere advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Taxotere advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. In addition, we cross-qualify all of our contacts, meaning any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to Taxotere chemotherapy treatment and side effects like permanent hair loss (alopecia), Leading Justice will increase your firm’s Taxotere case load. If you are interested in helping victims of alleged Taxotere side effects, our immeasurable consumer reach and direct advertising strategies give you the competitive edge and confidence to allocate your full budget and rest easy knowing your money is being used wisely.
Each and every law firm we work with at Leading Justice plays a role in determining how we categorize claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, we will customize our Taxotere case intake specifications to the exact criteria you are seeking. So, if your firm has specific Taxotere qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients a unique opportunity for internal cash buys of Taxotere data with no chance of fraud.
Taxotere Side Effect Litigation
There are approximately three million women in the United States with a history of breast cancer, and statistics show that close to 75% of those women are prescribed the chemotherapy medication Taxotere (docetaxel), which belongs to a class of cancer drugs called taxanes. Taxotere was approved by the U.S. Food and Drug Administration (FDA) for use in the United States in 1996, and is currently manufactured by pharmaceutical giant Sanofi-Aventis. Like most other chemotherapy drugs, which are designed to prevent harmful cancer cells from growing and dividing, Taxotere typically causes hair loss, and Sanofi-Aventis indicates on the drug warning label that “hair generally grows back” after completing treatment. Research, however, has shown that hair loss from Taxotere treatment may actually be permanent for up to 15% of users.
In addition to the obvious physical effects of Taxotere hair loss complications, women who experience alopecia that persists after chemotherapy treatment has been completed may also suffer psychological damages associated with their permanent baldness. In light of this serious issue, women who were prescribed the chemotherapy drug Taxotere, and who have since suffered permanent hair loss from the treatment regimen are now pursuing legal claims against Sanofi-Aventis, alleging that the drug maker failed to adequately warn consumers and healthcare providers about the risk of permanent baldness from Taxotere. As more women become aware of the alleged risk of permanent hair loss associated with Taxotere treatment, product liability lawsuits are expected to be filed against Sanofi-Aventis in courts across the country.